Introduction
Pulmonary complications occur in nearly half of all patients undergoing hematopoietic SCT. 1 These complications, occurring early or late in the post-transplant course, range from pulmonary edema, hemorrhage, engraftment syndrome, bronchiolitis obliterans, GVHD to, most commonly, infection. Since the advent of chemoprophylaxis against Pneumocystis carinii and preemptive or prophylactic strategies against CMV, currently the most common infectious organisms include invasive mold, adenovirus and bacterial pathogens. [2] [3] [4] Pulmonary infections are often treated empirically, presumptively diagnosed based on clinical signs and symptoms, radiographic findings and noninvasive microbiological results, including assessment of DNA or RNA viremia, b-D-glucan and Aspergillus galactomannan Ag. Although bronchoscopy and biopsy would ideally be undertaken, thrombocytopenia and unstable hemodynamic and pulmonary status often preclude their safe undertaking in this patient population. Nevertheless, aggressive pursuit of infected tissue for pathology and culture has the potential to clarify the infecting organism and reduce empiric antimicrobial therapy. We describe two cases in which classic presentations suggested invasive mold. Instead, biopsy results indicated Legionella jordanis.
Patients and methods
The first patient was a 30-year-old West-Indian man with Ph chromosome-positive CML who underwent a 5/6 HLAmismatched unrelated BMT, T cell depleted with the T10B9 MoAb and complement. 5 His cytoreduction consisted of TBI, cytarabine and CY. He received cyclosporine and corticosteroids for GVHD prophylaxis as described previously. 5 The patient developed biopsy-proven skin GVHD on day þ 31, which was treated successfully with topical and systemic steroids and the anti-IL-2 receptor, daclizumab.
On transplant day 69, the patient was hospitalized owing to fever, cough and 12-pound weight loss. Chest radiograph showed a focal nodular density in the superior segment of the right lower lobe (Figure 1) . A chest computed tomography (CT) scan demonstrated a single 3-cm round mass ( Figure 2 ). The patient was treated with ticarcillin/ clavulanate and amikacin, continued on itraconazole, and amphotericin B deoxycholate was added owing to concern regarding subtherapeutic serum itraconazole levels. A random measurement of the itraconazole level on hospital day 9 was o0.5 mcg/mL, prompting a 33% increase in itraconazole dose. Bronchoscopy performed on hospital day 6 (day þ 75) was non-diagnostic. The patient had resolution of fever and cough, and a chest CT scan performed 1 week after initiation of broad-spectrum therapy showed the presence of a smaller pulmonary nodule (1.7 cm) with central cavitation (Figure 3) . The patient was discharged on hospital day 21 to complete an additional week of double antifungal coverage.
At 48 h after discharge, the patient was readmitted with fever, lethargy and cough, and crackles in the right midaxilla and lung base. WBC count on admission was 3.9 cells/mm 3 , with absolute neutrophil and lymphocyte counts of 3.5 and 0.1 cells/mm 3 , respectively. Lymphoid phenotyping showed a circulating CD4 cell count of 4/mL. His chest CT scan showed an increase in the number and size of right lower lobe pulmonary nodules, many of which were cavitary (Figure 4 ). His serum cryptococcal Ag was negative. The patient was continued on itraconazole; his amphotericin B deoxycholate was changed to liposomal amphotericin B. Two weeks following admission, he underwent a right-sided video-assisted thoracoscopic surgery (VATS) with right lower lobe wedge resection. Pathology showed interstitial pneumonitis. The biopsy was negative for granulomas or viral inclusions, but showed rare bacillary forms on modified Steiner stain. Immunoperoxidase stains for CMV, EBV, adenovirus and toxoplasmosis were negative. Special stains for acid-fast bacteria and fungi were negative. Culture grew L. jordanis. Urine Legionella Ag was negative. In light of these findings, antimicrobial therapy was modified to include azithromycin. Further history revealed that the patient took frequent long showers at home and in the hospital. Unfortunately, the patient subsequently developed CMV viremia and multiple small central nervous system lesions suggestive of cerebral toxoplasmosis and/or aspergillus, as well as new bilateral alveolar infiltrates and pleural effusions. Despite broad-spectrum antimicrobial therapy, diuresis and oxygen support, his respiratory status deteriorated. He died on day 149 post hematopoietic stem cell transplant (HSCT). His family declined autopsy. The second patient is a 17-year-old boy with Fanconi anemia who received an 8/10 HLA-matched unrelated T-cell-depleted transplant for myelodysplastic syndrome with clonal evolution. His cytoreduction consisted of single low-dose TBI, fludarabine and low-dose CY as described previously. 6 His graft rejection prophylaxis consisted of pre-transplant rabbit anti-thymocyte globulin and shortcourse tacrolimus with rapid taper. His cytoreduction was truncated secondary to respiratory and hemodynamic decompensation of unknown etiology. His post-transplant course was complicated by vancomycin-resistant Enterococcus bacteremia on day þ 8 post HSCT and EBV (peak copy number was 535 000 copies/mL on day þ 62). His EBV viremia was treated successfully with five doses of rituximab.
On day 104 post transplant, the patient presented with acute onset of right-sided pleuritic chest pain following a minor car accident. On physical examination, he was afebrile, tachycardic. His lungs were clear, he was not tachypneic and his oxygen saturation was normal on room air. His chest X-ray demonstrated a right middle-lobe opacification ( Figure 5 ). CT scan showed a subpleural parenchymal opacification with a suggestion of peripheral ground glass halo, felt to be consistent with a fungal infection ( Figure 6 ). He had a normal WBC count, Hb, mild thrombocytopenia, normal electrolytes, elevated liver enzymes and an elevated sedimentation rate of 41 mm/h. His admission medications included low-dose tacrolimus, micafungin, pentamidine prophylaxis and weekly hyperimmune CMV Ig. He was started on linezolid, cefepime, liposomal amphotericin B and continued on micafungin. His blood culture grew coagulase-negative staphylococcus, after which his central line was removed.
Owing to the patient's lack of fever or cough, and immunodeficiency (CD4 count 140 cells/mL, T-cell proliferative response o10% of the lower limit of normal and absence of circulating B cells), the patient underwent a needle biopsy of his lung lesion. Purulent material was drained from the lesion, which grew L. jordanis on buffered charcoal yeast extract agar (Figure 7) . The identity of the organism was confirmed at the Centers for Disease Control by 98% homology in the macrophage infectivity potentiator genes. 7 Legionella urinary Ag was negative. Pathology of the fluid revealed many histiocytes, granulocytic infiltration and epithelioid histiocytes consistent with granulomatous inflammation. He was treated with levofloxacin for 3 weeks, following which CT scan showed resolution of lesions. The patient is now 20 months post-transplant, clinically well, with an absolute CD4, CD8 and CD19 cell count of 161, 642 and 222 cells/mL, respectively. His PHA response is 85% of the lower limit of normal.
Discussion
These two cases emphasize the need for definitive diagnosis in patients with nodular infiltrates, particularly cavitary, in whom other supporting laboratory findings such as Aspergillus galactomannan and/or b-D-glucan assay are negative, particularly if there is lack of response to antifungal therapy. In addition, it emphasizes the potential role of L. jordanis as a pulmonary pathogen in immunocompromised patients. In both cases, patients presented with lesions on chest CT scan that were suggestive of invasive pulmonary aspergillosis. In a study of 235 patients with invasive pulmonary aspergillosis, 8 94% had at least one pulmonary macronodule and 61% had a halo sign (a macronodule surrounded by ground glass opacity Legionella jordanis in HSCT patients R Meyer et al representing a discrete nodule with infarction and coagulative necrosis surrounded by alveolar hemorrhage). Aspergillosis is the most common cause of the halo sign in immunocompromised individuals, although this sign has been described in patients with Pseudomonas aeruginosa and Zygomycetes species. 8, 9 Because pulmonary aspergillosis carries a high morbidity and mortality, the halo sign is often used as a surrogate for early infection. Patients who are treated based on the presence of a halo sign have better survival (79 vs 53%) and response to treatment (52 vs 29%) than patients without halo signs. 8 However, L. pneumophila can often present as ground glass opacities next to discrete areas of consolidation on chest CT scan. 8, 9 L. jordanis was first isolated in 1978 from the Jordan River in Indiana following an outbreak of Legionnaire's disease in that region. The same researchers isolated a second strain 2 years later from a sewage plant in Georgia. 10 Since that time there have been only two case reports of culture-proven human infection with L. jordanis, none of which have been described in HSCT recipients.
11,12
The two culture-proven reports of L. jordanis in the literature were in patients who were not immunocompromised at baseline, although they had evidence of underlying lung disease. One patient was a 79-year-old man with progressive hyaline membrane disease and focal necrotizing pneumonitis. 11 The second patient was a 53-year-old man with chronic cough and a 'tree-in-bud' finding on chest CT. 12 Although neither of these patients had cavitary lesions, there is evidence that other types of Legionella, including L. pneumophila, are more likely to cause cavitation in immunocompromised individuals. 13 Additionally, cavitary Legionella infection is more common in patients on steroid therapy; for example, there is a reported case of L. bozemanii cavitary lesion in a pediatric patient undergoing allogeneic SCT.
14 This case expands our knowledge of the role of L. jordanis as a pathogen in immunocompromised hosts, especially its ability to cause cavitary lesions and its possible growth with the discontinuation of trimethoprim-sulfamethoxazole in the setting of HSCT.
Although there are two cases of culture-proven L. jordanis in the literature, there are additional cases that are suggestive of L. jordanis based on fourfold increase in titers to at least 1:128. In general, there is a low level of seroprevalence to Legionella species in healthy populations. 15 Other features may also help support a serologic diagnosis. For example, a 19-year-old woman diagnosed by serology in Israel also had L. jordanis cultured from her showerhead. 16 However, a 78-year-old smoker in Thailand diagnosed by serology had slightly elevated levels of other Legionella titers, although titers to L. jordanis were the most significant. There is also evidence that pseudomonal infection can elevate Legionella titers, thereby making serologic testing less helpful in diagnosis. 17 Additionally, serologic testing is often not helpful in patients who have undergone HSCT and have not yet achieved full immune reconstitution.
L. jordanis has only been described in water sources, and there has been concern for nosocomial transmission of this organism. At the time of presentation, the first patient had been out of the hospital for 6 weeks. However, Legionella species that reacted with antisera for both L. jordanis and L. bozemanii group 2 were isolated from showerheads in two rooms where the patient had resided. Molecular typing was not performed on the patient's isolate and the showerhead isolates, so it is unclear from where the patient acquired this organism. In response to these findings, monthly thermal-chlorine disinfection was instituted, but 19% of the showerheads remained positive for Legionella. A copper-silver ionization unit was then installed; monthly follow-up for 1 year revealed no isolation of Legionella. Our institution's water system continues to be monitored routinely. 18 Of note, there were 43 cases of Legionella reported in NYC in June 2009 and 58 cases in July 2009. 19 All of these cases except ours were L. pneumophila serogroup 1, diagnosed mostly by Legionella urine Ag. 20 These cases illustrate the importance of tissue diagnosis in unusual or refractory infections. A retrospective analysis of 174 patients following HSCT showed that fiberoptic bronchoscopy was diagnostic in 42.1% of patients and changed the management in 31.6% of patients (including the patient profiled in our first case). Although this study was performed to assess the utility of bronchoscopy in the diagnosis of CMV and pneumocystis carinii (PCP) infection, it instead revealed the broader spectrum of infection in post-HSCT patients and the need for definitive diagnosis. 1 In summary, we describe two cases of culture-proven L. jordanis, the first described in HSCT recipients. In patients deemed too unstable to undergo bronchoalveolar lavage (BAL) and/or lung biopsy, treatment for this organism should be considered.
